Novartis to expand oncology portfolio with acquisition of Mariana Oncology
Novartis has announced a significant move in the oncology sector with its agreement to acquire Mariana Oncology, a preclinical-stage biotechnology company based in Watertown, Massachusetts. ... Read More
Novartis gets Pluvicto EC approval for advanced prostate cancer
Novartis has received the approval of the European Commission (EC) for Pluvicto (lutetium (177Lu) vipivotide tetraxetan), a targeted radioligand therapy for advanced prostate cancer. Following ... Read More
Novartis completes $2.1bn acquisition of Endocyte to boost cancer treatment capabilities
Swiss pharmaceutical giant Novartis has officially closed its $2.1 billion acquisition of US-based biopharma company Endocyte, solidifying its position as a leader in radiopharmaceuticals for ... Read More
Novartis to expand radiopharmaceuticals portfolio with $2.1bn Endocyte acquisition
Swiss pharmaceutical company Novartis has announced a strategic acquisition of the US-based biopharma firm Endocyte for approximately $2.1 billion. This move aims to bolster Novartis’s ... Read More